Innoviva (INVA) Operating Leases (2019 - 2026)
Innoviva (INVA) reported Operating Leases of $10.7 million for Q1 2026, up 879.29% on a YoY basis from $1.1 million in Q1 2025, and down 1.69% quarter-over-quarter from $10.9 million in Q4 2025.
Innoviva (INVA) Operating Leases (2019 - 2026) Analysis & Trends
Innoviva has reported Operating Leases for 6 years, with the latest figure at $10.7 million in Q1 2026.
- For the quarter ending Q1 2026, Operating Leases rose 879.29% year-over-year to $10.7 million; the trailing twelve-month figure through Mar 2026 stood at $10.7 million (up 879.29% YoY), and the FY2025 full-year result was $10.9 million, up 821.8% from the prior year.
- Operating Leases for Q1 2026 stood at $10.7 million, down from $10.9 million in the prior quarter.
- The five-year high for Operating Leases was $10.9 million in Q4 2025, with the low at $905000.0 in Q3 2025.
- Historically, Operating Leases has averaged $2.9 million across 5 years, with a median of $2.0 million in 2023.
- Annual changes were most pronounced in 2025 — Operating Leases slumped 49.57% — and 2026, when it jumped 879.29%.
- Innoviva's Operating Leases stood at $2.4 million in 2022, then slumped by 31.19% to $1.6 million in 2023, then decreased by 27.89% to $1.2 million in 2024, then jumped by 821.8% to $10.9 million in 2025, then fell by 1.69% to $10.7 million in 2026.
- The last three Operating Leases figures came in at $10.7 million (Q1 2026), $10.9 million (Q4 2025), and $905000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - |
| 10 | Innoviva | 1.69 Bn | 1.08 Bn | 75.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.68 Mn |
| Dec 31, 2025 | 10.87 Mn |
| Sep 30, 2025 | 905,000.00 |
| Jun 30, 2025 | 1.00 Mn |
| Mar 31, 2025 | 1.09 Mn |
| Dec 31, 2024 | 1.18 Mn |
| Sep 30, 2024 | 1.59 Mn |
| Jun 30, 2024 | 1.98 Mn |
| Mar 31, 2024 | 1.30 Mn |
| Dec 31, 2023 | 1.64 Mn |
| Sep 30, 2023 | 1.95 Mn |
| Jun 30, 2023 | 1.86 Mn |
| Mar 31, 2023 | 2.10 Mn |
| Dec 31, 2022 | 2.38 Mn |
| Sep 30, 2022 | 2.70 Mn |
| Jun 30, 2022 | 3.09 Mn |
| Mar 31, 2022 | 3.30 Mn |
| Jun 30, 2019 | 1.16 Mn |
| Mar 31, 2019 | 1.24 Mn |